Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $66.00 Consensus Price Target from Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned an average recommendation of “Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $66.00.

Several research firms recently issued reports on MAZE. HC Wainwright lifted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, JPMorgan Chase & Co. upped their target price on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st.

Insider Buying and Selling

In other news, CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total value of $436,809.10. Following the completion of the sale, the chief marketing officer directly owned 14,609 shares in the company, valued at $436,809.10. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 141,470 shares of company stock worth $3,887,939. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Maze Therapeutics during the first quarter worth approximately $57,000. Goldman Sachs Group Inc. purchased a new position in Maze Therapeutics during the 1st quarter valued at about $145,000. Rhumbline Advisers acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $80,000. Geode Capital Management LLC lifted its stake in shares of Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after buying an additional 18,773 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares during the period.

Maze Therapeutics Trading Down 2.8%

Shares of MAZE stock opened at $28.49 on Friday. The firm has a 50 day moving average price of $27.03 and a two-hundred day moving average price of $34.59. Maze Therapeutics has a 12-month low of $12.81 and a 12-month high of $53.65. The company has a market capitalization of $1.58 billion, a PE ratio of -11.26 and a beta of 2.14. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. As a group, analysts predict that Maze Therapeutics will post -2.73 earnings per share for the current year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.